Reported Reactions

Adverse event reports that FDA received

  • Search
  • Watch list

Macular degeneration adverse event reports that record this term

Kind of term
MedDRA preferred term
Plain meaning
a disease of the central retina

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on . The data have the reports that FDA received through .

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on .

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 11,729 adverse event reports that record the MedDRA preferred term Macular degeneration. In plain words, the term means: a disease of the central retina. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 733 reports in the 12 months to June 2026 and 844 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Plain meaning

A disease of the central retina. The words are from the fixed dictionary of this site. They add nothing to a report.

Data version

openFDA FAERS release of 1 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 128 drug pages with 100 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.

Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of . The site read the page on .

Drugs that the reports with the term Macular degeneration name as a suspect product, in order of name
DrugClassReports with this term
Acetaminophen750
AdalimumabTumor necrosis factor blocker411
Alpha -Tocopherol D-184
AlprazolamBenzodiazepine803
AmoxicillinPenicillin-class antibacterial298
Amoxicillin trihydrate575
AspirinNonsteroidal anti-inflammatory drug335
Atorvastatin177
Atorvastatin calciumHMG-CoA reductase inhibitor650
Atropine sulfateAnticholinergic185
Atropine Sulfate Diphenoxylate Hydrochloride308
Avamys143
AzithromycinMacrolide antimicrobial450
Azithromycin Anhydrous265
Azithromycin dihydrateMacrolide antimicrobial187
BactrimDihydrofolate reductase inhibitor antibacterial252
Bactroban109
Benzydamine133
Betamethasone293
Betamethasone dipropionateCorticosteroid516
Betamethasone valerateCorticosteroid622
Biaxin455
Bisacodyl760
BudesonideCorticosteroid702
Calcium carbonateBlood coagulation factor421
Calcium Carbonate Cholecalciferol257
Calcium gluconateBlood coagulation factor104
Carboxymethylcellulose sodium337
CetirizineHistamine-1 receptor antagonist245
Cetirizine hydrochlorideHistamine-1 receptor antagonist572
Cholecalciferol238
ClarithromycinMacrolide antimicrobial784
ClotrimazoleAzole antifungal782
Cupric oxide356
DesonideCorticosteroid762
DilaudidOpioid agonist333
DiphenhydramineHistamine-1 receptor antagonist451
Diphenhydramine hydrochlorideHistamine-1 receptor antagonist427
DupixentInterleukin-4 receptor alpha antagonist152
EliquisFactor Xa inhibitor199
Elmiron203
EnbrelTumor necrosis factor blocker237
Entocort340
EntyvioIntegrin receptor antagonist132
ErgocalciferolProvitamin D2 compound699
ErtapenemPenem antibacterial123
Ertapenem sodiumPenem antibacterial661
EyleaVascular endothelial growth factor inhibitor105
FloventCorticosteroid548
FluticasoneCorticosteroid106
Fluticasone furoateCorticosteroid586
Fluticasone propionateCorticosteroid208
ForteoParathyroid hormone analog182
FosamaxBisphosphonate159
GlycerinNon-Standardized chemical allergen574
Gramicidin219
Gramicidin Neomycin Sulfate Polymyxin B Sulfate332
HumalogInsulin analog375
Humira1,305
Humulin NInsulin100
HydrochlorothiazideThiazide diuretic690
HydrocortisoneCorticosteroid137
Hydromorphone102
Hydromorphone hydrochlorideOpioid agonist418
ImbruvicaKinase inhibitor149
InfliximabTumor necrosis factor blocker113
Kenalog143
LantusInsulin analog146
Lantus SolostarInsulin analog187
LomotilAnticholinergic144
Loperamide136
Loperamide hydrochlorideOpioid agonist246
LucentisVascular endothelial growth factor inhibitor266
Lyrica124
Magnesium120
Magnesium oxideCalculi dissolution agent196
Magnesium sulfateCalculi dissolution agent439
MesalamineAminosalicylate586
Methylprednisolone sodium succinateCorticosteroid103
MetronidazoleNitroimidazole antimicrobial800
MidazolamBenzodiazepine117
Morphine sulfateOpioid agonist731
Mupirocin721
Nadololbeta-Adrenergic blocker799
Neomycin sulfateAminoglycoside antibacterial176
NexiumProton pump inhibitor103
Nicoderm CqCholinergic nicotinic agonist747
NicotinamideCopper-containing intrauterine device189
NicotineCholinergic nicotinic agonist543
Nicotine polacrilexCholinergic nicotinic agonist551
Nicotine transdermal system patchCholinergic nicotinic agonist158
NitroglycerinNitrate vasodilator198
PantoprazoleProton pump inhibitor527
Pantoprazole sodiumProton pump inhibitor156
PentasaAminosalicylate350
Polyethylene Glycol 3350 Potassium Chloride Sodium Bicarbonate Sodium141
Polyethylene glycol 4000105
Polyethylene Glycols147
Polymyxin b sulfate150
Potassium chlorideOsmotic laxative312
PrednisoneCorticosteroid840
Pregabalin765
Pulmicort Turbuhaler402
Refresh Tears645
RemicadeTumor necrosis factor blocker106
RevlimidThalidomide analog161
SimvastatinHMG-CoA reductase inhibitor203
SkyriziInterleukin-23 antagonist110
Sodium bicarbonateOsmotic laxative251
Sodium bicarbonate, sodium chlorideOsmotic laxative368
Sodium chlorideOsmotic laxative466
Sucralfate123
Sulfamethoxazole and trimethoprimDihydrofolate reductase inhibitor antibacterial189
Sulfamethoxazole, trimethoprimDihydrofolate reductase inhibitor antibacterial438
SymbicortCorticosteroid140
Tiotropium bromideAnticholinergic278
Triamcinolone193
Triamcinolone acetonideCorticosteroid762
TrimethoprimDihydrofolate reductase inhibitor antibacterial134
Ubidecarenone104
ValsartanAngiotensin 2 receptor blocker224
Vitamin dProvitamin D2 compound121
Vitamin eVitamin C119
Xantofyl Palmitate408
XeljanzJanus kinase inhibitor132
Zeaxanthin376
Zinc oxide442
Zopiclone116

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 48 pharmacologic classes with 100 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.

Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of . The site read the page on .

Pharmacologic classes of the drugs that the reports with the term Macular degeneration name, in order of name
ClassReports with this term
Aminoglycoside antibacterial221
Aminosalicylate962
Angiotensin 2 receptor blocker356
Anticholinergic774
Antimalarial119
Azole antifungal938
Benzodiazepine968
beta-Adrenergic blocker859
Bisphosphonate250
Blood coagulation factor534
Calculi dissolution agent725
Cholinergic muscarinic antagonist145
Cholinergic nicotinic agonist2,004
Copper-containing intrauterine device189
Corticosteroid6,417
Dihydrofolate reductase inhibitor antibacterial1,023
Factor Xa inhibitor332
Fluoroquinolone antibacterial181
Folate analog metabolic inhibitor124
GLP-1 receptor agonist213
Histamine-1 receptor antagonist1,739
HMG-CoA reductase inhibitor999
Insulin212
Insulin analog1,077
Integrin receptor antagonist229
Interleukin-23 antagonist110
Interleukin-4 receptor alpha antagonist180
Janus kinase inhibitor251
Kinase inhibitor325
Macrolide antimicrobial1,423
Nitrate vasodilator198
Nitroimidazole antimicrobial834
Non-Standardized chemical allergen586
Nonsteroidal anti-inflammatory drug402
Opioid agonist2,085
Osmotic laxative1,573
Parathyroid hormone analog188
Penem antibacterial817
Penicillin-class antibacterial298
Phosphodiesterase 5 inhibitor105
Prostaglandin analog107
Proton pump inhibitor851
Provitamin D2 compound820
Thalidomide analog187
Thiazide diuretic690
Tumor necrosis factor blocker939
Vascular endothelial growth factor inhibitor544
Vitamin C192

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Macular degeneration, by month, five years to June 2026
010020020222023202420252026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Macular degeneration
AgeReportsShareShare as a bar
Under 200%
2 to 115under 0.1%
12 to 17120.1%
18 to 442071.8%
45 to 649227.9%
65 to 741,68214.3%
75 and over3,10726.5%
Age not given5,79449.4%
Sex of the patient in the reports that record Macular degeneration
SexReportsShareShare as a bar
Female8,20770%
Male2,67422.8%
Unknown or not given8487.2%

Age and sex are as the report gives them. 70.3% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

The site checked these addresses on . The links open in a new tab.

Cite this page

Reported Reactions. Macular degeneration: adverse event reports that record this term. https://reportedreactions.com/reaction/macular-degeneration/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of . Reports received through .

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 1 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Oct 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Macular degeneration mean in an adverse event report?

In plain words: a disease of the central retina. It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.

Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on .